StreetAlpha.app
Home › Stocks › BMEA

Biomea Fusion, Inc. (BMEA)

Healthcare
$0.48
▼ −8.00%
LAST CLOSE · NOV 17

Biomea Fusion develops oral drug candidates to treat diabetes and obesity. It last closed at $0.48 on Nov 17, down 8.00% on the day. The average 12-month price target from 3 analysts is $7.00 (+1362.9% from the last close), with a high of $10.00 and a low of $4.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is BMEA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$22.3M
EPS (diluted)
−$0.10
Valuation
Market cap
$34.8M
72.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$26.4M
At Sep 30
Shareholder equity
$7.6M
Shares outstanding
72.7M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$41.6M−$41.6MFY2021FY2022: −$81.8M−$81.8MFY2022FY2023: −$117.3M−$117.3MFY2023FY2024: −$138.4M−$138.4MFY2024FY2025: −$61.8M−$61.8MFY2025

From BMEA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on BMEA in the past 90 days
Average 12-month target
$7.00
▲ 1362.9% upside

Based on 3 analysts who set a price target on BMEA in the past 90 days. The average target is $7.00, with a high of $10.00 and a low of $4.00, compared with the last close of $0.48.

Low $4.00Avg $7.00High $10.00
Blue marker: last close $0.48
Highest target$10.00
Average target$7.00
Lowest target$4.00
Latest rating changes
CitizensTarget lowered
Oct 14Buy$9 → $7
HC Wainwright & Co.Reiterated
Oct 14Buy$4
Brookline CapitalInitiated
Oct 7Buy$10
CitizensInitiated
May 5Buy$9
DateFirmActionRatingPrice target
Oct 14CitizensTarget loweredBuy$9 → $7
Oct 14HC Wainwright & Co.ReiteratedBuy$4
Oct 7Brookline CapitalInitiatedBuy$10
May 5CitizensInitiatedBuy$9
Loading…

Technical Analysis

BMEA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 26% below its 20 day and 125% below its 50 day average. It is 178% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.46, and the nearest resistance the Pivot at $0.50.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.2%/day
Key levels
$2.2452 week high+366.7%
$1.33200 day average+177.1%
$1.24100 day average+158.3%
$1.0750 day average+122.9%
$0.62Swing high (Nov 11)+29.2%
$0.6020 day average+25.0%
$0.53Pivot R1+10.4%
$0.50Pivot+4.2%
$0.48Last close
$0.4652 week low−4.2%
$0.44Pivot S1−8.3%
Indicators
RSI (14)28.20Oversold below 30Oversold
MACD-0.14Above its signal lineBullish
Stochastic11.8Near the bottom of its rangeOversold
ADX (14)46.5Strong downtrend
Williams %R-93.3Oversold below −80, overbought above −20Oversold
CCI (20)-202.4Oversold below −100, overbought above 100Oversold
Rate of change−24.3%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 17.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BMEA

What happened before

See how BMEA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BMEA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BMEA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BMEA in the last 90 days.

Loading…

See today’s whale options flow across the market →

BMEA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 22 selling
  • ▲Held by funds +2.1 pts
  • ▲Funds holding +9
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7162+14.5%
In funds' top 10110.0%
Held by funds37.2%35.1%+2.1 pts
New / increased15 / 178 / 21+10.3%
Reduced / sold out17 / 511 / 14−12.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BMEA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMEA is in one of them and how their past BMEA trades turned out.

BMEA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BMEA in an article yet. Here's the latest on the wider market.

About Biomea Fusion

Biomea Fusion is a drug developer focused on treatments for diabetes, obesity, and related metabolic diseases. Its work centers on two experimental medicines taken by mouth: icovamenib, which is being studied in type 1 and type 2 diabetes, and BMF-650, a next generation GLP-1 receptor agonist being developed for obesity. The company is based in San Carlos, California, and its target customers are patients with these conditions and the doctors who treat them. Both medicines are still in clinical development.

Headquarters
San Carlos, CA